The idea is old enough to have a smell of the 1970s about it, and simple enough that you can explain it at a bar. Wernicke encephalopathy, and the dense amnesia of Korsakoff syndrome that so often follows it, is caused by a shortage of one cheap water-soluble vitamin. Heavy drinkers run short of thiamine for several reasons at once: they eat less, they absorb less, and they burn through what they have. The medicine that prevents the brain damage costs pennies. The problem has never been the molecule. The problem is delivery. In 1978, Brandon Centerwall and Michael Criqui published a cost-benefit analysis in the New England Journal of Medicine that took the obvious next step: if the people at risk will not come to the vitamin, put the vitamin where they already are. They estimated the annual incidence of institutionalisation for the syndrome at eight per million adults, priced long-term institutional care at 70 million dollars a year in present value, and priced adequate fortification of alcoholic drinks at between 3 and 17 million dollars a year depending on the compound used. The ratio, they wrote, ran somewhere between 1 to 23 and 1 to 4 in favour of doing it.
Australia is where the argument stopped being theoretical. Clive Harper and colleagues, in a prospective necropsy study published in the Journal of Neurology, Neurosurgery and Psychiatry in February 1989, found Wernicke-Korsakoff syndrome in the brains of 2.1 percent of Sydney adults coming to autopsy. That is not a survey of patients. That is a count of what was actually in people's heads, most of it never named while they lived. The commentary that revives all this, by Thomas Jedamzik and Georg Juckel of Ruhr University Bochum, published in Drug and Alcohol Dependence Reports on 4 July 2025, traces how the Australian debate then unfolded: technical trials in 1979 and 1981 found no meaningful taste change from thiamine in beer; allithiamines, briefly favoured for their bioavailability, turned out to be unsuitable because their sulphur bonds broke down in beer; and in 1987 Price and colleagues proposed a concrete working dose of 0.5 mg per 740 mL bottle. A later double-blind triangular taste test by Phillip Stacey and Karen Sullivan, published in Alcohol and Alcoholism in July 2003 with 49 volunteers, found that fortified beer could not be reliably picked out from ordinary beer, though tasters did rate it as more bitter. Small study, narrow question, but it is the kind of fact that kills an objection.
What killed the proposal was not chemistry. At a 1990 workshop the medical disciplines were in favour and the nutritionists and dietitians were against, and no consensus emerged; there was, however, strong support for fortifying cereals. Beginning 1 January 1991, Australian bread-making flour was fortified with thiamine. The compromise was the thing that got done. And here is the part that makes this a natural experiment rather than a debating point. Ma and Truswell, reviewing records from 17 major Sydney public hospitals from 1978 to 1993 (published in the Medical Journal of Australia in November 1995), found 1,267 patients with the syndrome, 1,012 of them acute, and reported that the last two years had the lowest acute counts of all sixteen; they were careful to write that this was consistent with a preventive effect but not conclusive evidence. Then Harper's group returned to the mortuary. In 2,212 sequential autopsies at the New South Wales Institute of Forensic Medicine across 1996 and 1997, published in the Medical Journal of Australia on 1 June 1998, they found 25 cases: a prevalence of 1.1 percent, roughly half the 1980s figure. Bread appears to have moved the number. That is about as clean a result as population nutrition policy ever produces.
Now the other half of the record, which matters more to families than the triumphant half. Australia's prevalence at 1.1 percent was still, the authors wrote, higher than in most other Western countries. Only four of the 25 cases, 16 percent, had been diagnosed while the person was alive. Rolland and Truswell, looking at the same Sydney hospitals for 1993 to 1996 in Public Health Nutrition in June 1998, still counted an average of 38 new acute cases and 69 total cases a year. And on the economics, Jedamzik and Juckel summarise Connelly and Price's 1996 modelling in the Australian and New Zealand Journal of Public Health, built on consumption data from 40 people with alcohol use disorder: fortifying flour came out at least 28 times more expensive per case averted than fortifying beer alone. Australia bought a real reduction, at a price, using the vehicle that heavy drinkers eat least of. Harper's team drew the cautious conclusion that further research was needed before adding thiamine to alcoholic drinks could be recommended. Twenty-eight years on, that research has not been done.
This belongs on a prevention page rather than a history page because the alternative strategy, telling clinicians to prescribe thiamine to the right patients, keeps failing in measurable ways. Sarah Baron and colleagues at Montefiore in the Bronx, reporting in the Journal of Substance Use and Addiction Treatment in August 2024, note that up to 75 percent of hospitalised inpatients with alcohol use disorder are prescribed no thiamine at all. Their own single-centre pre-post study, covering 5,307 admissions with alcohol-related diagnoses in the year before and the year after they built a prompt into the electronic ordering screen, did significantly improve things: high-dose thiamine in the first 24 hours went from 1.1 percent of such admissions to 4.7 percent, an adjusted odds ratio of 4.50. Read that twice. A successful quality-improvement intervention, and the ceiling it reached was under one admission in twenty. And every one of those numbers only counts people who reached a hospital bed in the first place. Fortification is the only version of this that does not require the person to present to services, to be asked the right question, or to be believed.
Jedamzik and Juckel are not reporting a trial, and they do not pretend to be. Theirs is a commentary and narrative history drawing on published studies, reviews and opinion pieces from the 1940s to now, and the objections they catalogue have not evaporated: that malabsorption in the sickest drinkers might blunt the benefit, that a vitamin-enriched label could nudge public beliefs about alcohol in the wrong direction, that regulators and exporters will not wear it. Their argument is that given no evidence of thiamine toxicity even at very high doses, and given how well other historic fortification programmes worked, running it as a trial looks defensible, and that the definitive data could probably only ever be gathered retrospectively, after someone has been brave enough to try. The counterfactual they mourn is specific: an isolated country with the political will, which had the moment and let it pass.